Trastuzumab Deruxtecan + Paclitaxel + Trastuzumab + Pertuzumab + Doxorubicin + cyclophosphamide
Phase 3Active 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Breast Neoplasms
Conditions
Breast Neoplasms, Breast Cancer, HER2-positive Early Breast Cancer
Trial Timeline
Oct 25, 2021 → Apr 30, 2027
NCT ID
NCT05113251About Trastuzumab Deruxtecan + Paclitaxel + Trastuzumab + Pertuzumab + Doxorubicin + cyclophosphamide
Trastuzumab Deruxtecan + Paclitaxel + Trastuzumab + Pertuzumab + Doxorubicin + cyclophosphamide is a phase 3 stage product being developed by Daiichi Sankyo for Breast Neoplasms. The current trial status is active. This product is registered under clinical trial identifier NCT05113251. Target conditions include Breast Neoplasms, Breast Cancer, HER2-positive Early Breast Cancer.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05113251 | Phase 3 | Active |
Competing Products
20 competing products in Breast Neoplasms